Tuberous Sclerosis Complex

• TSC1/TSC2 Complex Function: The TSC1 and TSC2 gene products form a heteromeric complex that acts as a negative regulator of mTORC1 (mTOR complex 1). This complex functions as a GTPase-activating protein (GAP) that converts active Rheb-GTP to inactive Rheb-GDP. Loss-of-function mutations in either TSC1 or TSC2 impair this GAP activity, leading to constitutive activation of Rheb-GTP and consequent uncontrolled mTORC1 signaling. mTORC1 activation promotes protein synthesis, ribosomal biogenesis, and inhibits autophagy, resulting in pathologic cell growth and proliferation.

• Hamartoma Formation and Growth: The cellular consequences of uncontrolled mTORC1 signaling include excessive protein synthesis, increased cell size (cytomegaly), loss of normal cell cycle checkpoints, and reduced apoptosis. These effects drive the formation of benign tumors (hamartomas) in affected tissues. In the brain, cortical tubers develop from abnormal neuronal differentiation and migration. Subependymal nodules (SENs) and subependymal giant cell astrocytomas (SEGAs) arise from dysregulated astrocytic proliferation. Renal angiomyolipomas result from proliferation of abnormal smooth muscle and adipose tissue. Cardiac rhabdomyomas arise from uncontrolled proliferation of cardiac myocytes. The multi-organ involvement reflects the ubiquitous expression of TSC1 and TSC2 throughout developing tissues.

• Neuronal Dysfunction and Seizure Pathogenesis: Cortical tubers consist of abnormally organized neurons, glial cells, and cells with giant cell morphology. These lesions contain markedly enlarged neurons (cytomegaly) with abnormal dendritic spines, disrupted axonal projections, and altered GABAergic inhibitory circuitry. The architectural disorganization creates foci of abnormal electrical excitability with impaired inhibition, predisposing to seizure generation. Additionally, mTORC1 hyperactivation impairs GABA synthesis and trafficking, further reducing inhibitory neurotransmission. White matter abnormalities, abnormal cortical lamination, and disrupted cortical-subcortical connectivity contribute to both seizure susceptibility and cognitive dysfunction. The seizures in TSC are often multifocal and can originate from both tubers and perituber regions, explaining their frequency and treatment resistance.

• TSC1 Gene Mutations (chromosome 11q13): Approximately 50-60% of TSC cases result from mutations in TSC1, which encodes the 130 kDa hamartin protein. TSC1 mutations are associated with relatively milder phenotypes in many studies, though substantial phenotypic overlap exists. Individuals with TSC1 mutations have lower rates of infantile spasms and earlier-onset seizures compared to historical data, though this varies across studies. TSC1 mutations include point mutations, insertions, deletions, and large genomic rearrangements that all result in loss of protein function.

• TSC2 Gene Mutations (chromosome 16p13.3): Approximately 40-50% of TSC cases result from mutations in TSC2, which encodes the 200 kDa tuberin protein. TSC2 mutations are generally associated with more severe phenotypes, including earlier seizure onset, higher seizure frequency, and greater cognitive impairment, though individual variation remains substantial. TSC2 mutations include point mutations, insertions, deletions, and large genomic deletions. Contiguous gene deletions involving TSC2 and adjacent genes (PKD1) can result in particularly severe renal disease phenotypes with early-onset polycystic kidney disease.

• De Novo Mutations and Somatic Mosaicism: Approximately 33% of TSC cases arise from de novo mutations without prior family history, affecting genetic counseling and recurrence risk. Somatic mosaicism occurs in 1-2% of parents of children with TSC, resulting from post-zygotic mutations present in a subset of somatic cells. Germline mosaicism can occur in parents with somatic mosaicism and carries recurrence risks of 1-2%, necessitating careful genetic counseling. The distinction between germline mutations (affecting all cells and carrying 50% transmission risk) and somatic mosaic mutations (affecting a subset of cells with variable transmission risk) is critical for family planning.

• Genetic Modifiers and Genotype-Phenotype Correlations: While TSC1 and TSC2 mutations represent primary determinants of disease, secondary genetic modifiers and epigenetic factors influence clinical severity. However, no specific modifying loci have been conclusively identified for routine clinical use. Environmental factors and developmental timing of somatic mutations in individual tissues influence hamartoma development and progression.

Neurological Manifestations

• Seizures (75-80% of patients): Often the most prominent clinical feature and frequently the presenting manifestation. Seizure onset typically occurs in infancy or early childhood, with infantile spasms (West syndrome) occurring in 10-15% of TSC patients. Seizure types are heterogeneous and include focal seizures, generalized tonic-clonic seizures, atypical absences, and myoclonic seizures. Multifocal seizures are common, reflecting multiple cortical foci. Seizures are often pharmacoresistant, with approximately 30% of patients being resistant to standard antiepileptic drugs. Status epilepticus and sudden unexpected nocturnal death in epilepsy (SUDEP) represent serious complications.

• Intellectual Disability and Developmental Delay (30-50% of patients, more common with TSC2 mutations): Ranges from mild learning difficulties to severe intellectual disability. Correlates with seizure severity, number of cortical tubers, and white matter abnormalities. Early seizure onset and prolonged seizure activity appear associated with worse cognitive outcomes. Autism spectrum disorder occurs in 30-50% of TSC patients, representing a major comorbid condition requiring specialized evaluation and management.

• Cortical Tubers (90% of TSC patients): Pathognomonic brain lesions visible on neuroimaging. These are areas of focal cortical dysplasia characterized by disorganized cortical architecture. Cortical tubers do not typically require specific treatment but serve as markers of disease severity and may correlate with seizure burden.

• Subependymal Nodules (SENs) (90% of TSC patients): Benign growths lining the walls of the lateral ventricles, arising from the caudothalamic groove. Most remain stable; however, progressive growth in some individuals warrants monitoring. SENs themselves do not typically require intervention.

• Subependymal Giant Cell Astrocytomas (SEGAs) (10-20% of TSC patients): Potentially life-threatening tumors that develop from subependymal nodules. Can obstruct cerebrospinal fluid (CSF) flow and cause obstructive hydrocephalus, leading to headaches, papilledema, and raised intracranial pressure. SEGAs may become clinically evident following seizure onset or may be detected incidentally on neuroimaging. Growth trajectory is unpredictable; some remain stable over years while others progress rapidly.

Cutaneous Manifestations

• Facial Angiofibromas (75-90% of patients): The most common skin manifestation, appearing as small red to flesh-colored papules in a "butterfly" distribution across the cheeks, nose, and chin. These typically emerge between ages 2-6 years. Formerly termed "adenoma sebaceum," a misnomer since they are actually angiofibromas without sebaceous gland involvement. Cosmetically disfiguring and can lead to significant psychological burden.

• Confetti Skin Lesions (10-20% of patients): Hypopigmented macules, often present at birth or emerging in infancy. Typically 1-3 mm in diameter, distributed randomly on trunk and extremities. Become more apparent with increasing skin pigmentation and are particularly noticeable in darker-skinned individuals.

• Ash-Leaf Spots (Hypomelanotic Macules) (50-80% of patients, often earliest sign): Hypopigmented patches of various shapes and sizes, present at birth or emerging in early infancy. Typically largest on trunk and proximal extremities. Best visualized with Wood's lamp (ultraviolet light) in lightly pigmented individuals. Represent clonal populations of melanocytes with reduced melanin production. Ash-leaf spots are the earliest clinical manifestation in many TSC patients and often present before seizure onset.

• Ungual or Periungual Fibromas (15-40% of patients): Small skin-colored growths arising from the nail beds or periungual tissue, typically appearing in adolescence or adulthood. Multiple lesions may develop over time.

• Café-au-lait Spots (10-15% of patients): Pigmented macules similar to those seen in neurofibromatosis but less prominent in TSC.

• Shagreen Patches (20-40% of patients): Areas of thickened, dimpled skin resembling untanned leather, typically appearing in lower back region or sacral area. Generally become more apparent with age. Usually asymptomatic but may rarely be associated with underlying spinal dysraphism.

Renal Manifestations

• Angiomyolipomas (AMLs) (80-90% of TSC patients): Benign tumors composed of abnormal smooth muscle, adipose tissue, and angiomatous vessels. Present in 80-90% of TSC patients and are bilateral in 80% of cases. Most remain small and asymptomatic; however, larger lesions (>4 cm) carry significant risk of spontaneous hemorrhage, potentially causing life-threatening retroperitoneal bleeding. Flank pain, hematuria, and anemia may indicate hemorrhage. Risk of hemorrhage increases with tumor size and presence of aneurysms within the lesion.

• Renal Cysts (15-20% of TSC patients): Simple cysts that are generally asymptomatic and do not typically progress.

• Renal Cell Carcinoma (RCC) (1-2% of TSC patients): Increased incidence compared to general population, though absolute risk remains low. Typically arises in setting of renal cystic disease. Warrants surveillance in adult TSC patients.

• Polycystic Kidney Disease (rare, TSC2/PKD1 contiguous deletions): Severe progressive renal cystic disease with potential progression to end-stage renal disease. Occurs in patients with large deletions involving both TSC2 and adjacent PKD1 genes.

Cardiac Manifestations

• Cardiac Rhabdomyomas (30-60% of TSC patients, more common in early life): Benign cardiac tumors arising from abnormal proliferation of cardiac myocytes. Often multiple and can be located in any cardiac chamber. Many are detected prenatally on fetal echocardiography. Most cardiac rhabdomyomas remain asymptomatic and regress spontaneously with age, though some persist into adulthood. Larger tumors may cause obstructive hemodynamic complications, arrhythmias, or sudden cardiac death, though this is uncommon.

• Arrhythmias (including Wolff-Parkinson-White syndrome): Associated with cardiac involvement and abnormal conduction pathways. Can predispose to sudden cardiac events.

Other Manifestations

• Pulmonary Lymphangioleiomyomatosis (LAM) (30-40% of women with TSC, rare in men): Progressive cystic lung disease affecting predominantly women of reproductive age. Characterized by abnormal proliferation of smooth muscle cells in the lungs, leading to progressive airflow obstruction and cystic destruction. Presents with progressive dyspnea, cough, and exercise limitation. Can rapidly progress to respiratory failure. Represents a leading cause of morbidity and mortality in adult women with TSC.

• Pancreatic Involvement: Pancreatic cysts (10-33% of patients) and rarely functional neuroendocrine tumors.

• Gastrointestinal Involvement: Hamartomatous growths in the stomach, small bowel, and colon; rarely cause obstruction or bleeding.

Clinical Diagnostic Criteria (Revised 2012 International TSC Consensus Conference)

• Cortical or subcortical tubers
• Cardiac rhabdomyoma
• Renal angiomyolipoma
• Lymphangioleiomyomatosis (LAM)
• Facial angiofibromas or forehead plaque
• Ungual or periungual fibromas
• Hypomelanotic macules (three or more)
• Shagreen patch
• Retinal hamartomas
• Confetti skin lesions

• Dental enamel pitting (>3 lesions)
• Intraoral fibromas
• Retinal achromatic patch
• Renal cysts
• Nonrenal hamartomas

Genetic Testing

• Molecular Testing: Direct DNA sequencing of TSC1 and TSC2 genes is the gold standard for genetic confirmation. Testing should be performed in patients meeting clinical diagnostic criteria, those with suspected disease not meeting full criteria, and asymptomatic relatives of affected individuals for predictive testing. Sequencing detects approximately 90% of pathogenic mutations; next-generation sequencing (NGS) panels improve detection of small insertions/deletions. Large genomic deletions detected by comparative genomic hybridization (CGH) or deletion-specific testing account for 5-10% of mutations not identified by standard sequencing.

• Interpretation: Identified variants are classified as pathogenic, likely pathogenic, variants of uncertain significance (VUS), likely benign, or benign according to American College of Medical Genetics (ACMG) guidelines. Novel variants in conserved protein domains with demonstrated loss-of-function mechanisms are generally classified as pathogenic.

Neuroimaging

• Magnetic Resonance Imaging (MRI) of Brain: The imaging modality of choice for comprehensive assessment of CNS involvement. Standard protocol should include T1-weighted, T2-weighted, and FLAIR sequences with attention to the infratentorial structures. MRI findings include:
• Cortical tubers: Regions of cortical dysplasia that appear hyperintense on T2/FLAIR sequences and often hypointense on T1. Typically multiple, bilateral, and affect the gray-white matter junction. May show calcification visible on CT.
• Subependymal nodules (SENs): Small nodular lesions along the ventricular wall, typically hypointense on T1 and isointense on T2. Most remain stable; growth warrants follow-up.
• Subependymal giant cell astrocytomas (SEGAs): Larger lesions (typically >1 cm) that may show growth into ventricular cavity, potential hydrocephalus from obstruction, and variable enhancement with gadolinium. Serial MRI imaging every 3-6 months is recommended for SEGAs to assess progression.
• White matter abnormalities: Regions of T2/FLAIR hyperintensity in the white matter unrelated to tubers, representing disrupted myelination or gli

Immediate stabilisation

• Obstructive hydrocephalus from a SEGA: a neurosurgical emergency — head CT/MRI, then CSF diversion (external ventricular drain) and resection. Medical therapy is too slow for a decompensating patient.
• Hemorrhaging angiomyolipoma (Wunderlich syndrome): resuscitate, then selective arterial embolization; the Consensus Group favors embolization over nephrectomy to preserve nephrons.
• Status epilepticus: benzodiazepine (lorazepam IV) then a second-line ASM, per standard status protocols.

First-line seizure therapy

• Vigabatrin is the drug of choice for infantile spasms in TSC (irreversible GABA-transaminase inhibitor), endorsed by the AAN/Child Neurology Society practice guideline and the International TSC Consensus; ACTH is the alternative and is preferred over vigabatrin only for non-TSC spasms.
• Preemptive vigabatrin when serial infant EEG shows epileptiform activity before clinical seizures — Consensus Group guidance based on EPISTOP.
• Focal seizures: conventional antiseizure medications (e.g., oxcarbazepine, levetiracetam) chosen as for focal epilepsy generally.

Escalation

• Cannabidiol: FDA-approved adjunct for TSC-associated seizures.
• Everolimus: mTORC1 inhibitor, FDA-approved as adjunctive therapy for refractory focal seizures, for SEGA not requiring urgent surgery, and for renal angiomyolipoma (treat growing lesions above roughly 3 cm rather than waiting for bleeding).
• Sirolimus: recommended by the ATS/JRS lymphangioleiomyomatosis guideline for LAM with abnormal or declining lung function.
• Ketogenic diet, vagus nerve stimulation, and resective epilepsy surgery for drug-resistant epilepsy after localization of the epileptogenic tuber.
• Topical sirolimus for facial angiofibromas; laser as an adjunct.

Avoid

• Estrogen-containing contraceptives in women with LAM (estrogen promotes LAM cell proliferation).
• mTOR inhibitors in pregnancy, and live vaccines while on them (immunosuppression).
• Nephrectomy for angiomyolipoma when embolization or mTOR inhibition will suffice.
• Continuing vigabatrin once confirmed visual field constriction develops.

Neurologic

• Obstructive hydrocephalus from SEGA growth (emergency): a tumor at the foramen of Monro blocks CSF egress; signals are new morning headache, vomiting, papilledema, declining school performance, or a change in baseline seizure pattern. Any of these in a known TSC patient mandates urgent imaging.
• Drug-resistant epilepsy, status epilepticus, and SUDEP: multifocal cortical dysplasia with impaired GABAergic inhibition means many patients fail two or more agents.
• TAND (TSC-associated neuropsychiatric disorders): autism spectrum disorder, ADHD, and intellectual disability; the Consensus Group recommends screening at every annual visit because these are systematically under-recognized.

Renal

• Angiomyolipoma hemorrhage (emergency): aneurysmal vessels within the lesion rupture, producing flank pain, hematuria, an expanding retroperitoneal hematoma, and hypovolemic shock. Renal disease is the leading cause of death in adults with TSC.
• Chronic kidney disease from cumulative parenchymal loss (tumors, cysts, prior surgery), and rarely renal cell carcinoma at a younger age than in the general population.

Pulmonary and cardiac

• Spontaneous pneumothorax or chylothorax in LAM (emergency if tension physiology): cystic destruction of lung parenchyma and lymphatic obstruction; sudden dyspnea and pleuritic pain in a young woman with TSC.
• **Rhabdomyoma-related outflow obstruction, arrhythmia, or accessory-pathway tachycardia (WPW)**; fetal tumors may cause hydrops.

Treatment-related

• Vigabatrin retinal toxicity: irreversible concentric peripheral visual field constriction, requiring baseline and periodic ophthalmologic testing; infants may also show reversible T2 hyperintensity in basal ganglia, thalamus, and brainstem on MRI.
• mTOR inhibitors (everolimus, sirolimus): aphthous stomatitis (often the first and dose-limiting toxicity), immunosuppression with infection, non-infectious pneumonitis, hyperlipidemia, hyperglycemia, and impaired wound healing.
• Cannabidiol: transaminase elevation, particularly with concomitant valproate, and sedation via elevated active clobazam metabolite.

• Infant with flexor spasms, hypsarrhythmia on EEG, and hypopigmented macules: the stem is TSC. The single best next step in therapy is vigabatrin — this is the one setting where vigabatrin outranks ACTH for infantile spasms.
• Ash-leaf spots are the earliest sign and are demonstrated with a Wood's lamp. Their presence in a seizing infant should prompt brain MRI, echocardiography, renal imaging, and ophthalmologic exam.
• Cardiac rhabdomyoma is the most common cardiac tumor of childhood and is frequently found prenatally; most regress spontaneously, so an asymptomatic rhabdomyoma is observed, not resected. Finding one obligates a TSC evaluation.
• Fat-containing renal mass on CT = angiomyolipoma. Macroscopic fat effectively excludes renal cell carcinoma. Large or aneurysmal lesions bleed — flank pain plus hematuria plus hypotension is Wunderlich syndrome.
• Mechanism examiners love: TSC1/TSC2 loss removes GAP activity on Rheb, leaving mTORC1 constitutively on — which is why rapamycin analogues (everolimus, sirolimus) shrink SEGAs, angiomyolipomas, and LAM lesions rather than merely palliating them.
• Young woman with TSC and recurrent spontaneous pneumothorax or chylous effusion: lymphangioleiomyomatosis. Avoid estrogen-containing contraceptives; sirolimus is the disease-modifying therapy per the ATS/JRS guideline.
• Common distractor — neurofibromatosis type 1. Both are autosomal dominant neurocutaneous disorders with café-au-lait macules, but Lisch nodules, axillary freckling, and neurofibromas point to NF1, whereas angiofibromas, shagreen patch, and periungual fibromas point to TSC. "Adenoma sebaceum" is an obsolete misnomer for facial angiofibromas.
• Do not attribute vision loss in TSC to retinal hamartomas by default — in a treated child, ask about *vigabatrin*-induced peripheral field constriction, which is irreversible and requires scheduled ophthalmologic monitoring.